States Move Forward with Public Option Programs, but Differ in How They Select Insurance Carriers


SB 5618

Protecting consumers from charges for out-of-network health care services, by aligning state law and the federal no surprises act and addressing coverage of treatment for emergency conditions.


SB 5532

Establishing a prescription drug affordability board. The Prescription Drug Affordability Board (Board) is established within HCA with five members appointed by the Governor, who have expertise in health care economics or clinical medicine. All meetings of the Board must be open and public, except for executive sessions. Affordability reviews must determine if the drug has led or will lead to excess costs, defined as costs exceeding therapeutic benefit relative to other treatments, or are not sustainable to
the health care system over a ten-year period.


HB 1728

Reauthorizing and amending dates for the total cost of insulin work group. The Total Cost of Insulin Work Group (Work Group) must submit a preliminary report detailing
strategies to reduce the cost of insulin by December 1, 2022. The Work Group must submit the final report to the Governor and Legislature by July 1, 2023. The Work Group expires on December 1, 2024.


How States Are Holding Payers And Providers Accountable For Health Cost Growth


Can State Prescription Drug Affordability Boards Address High-Cost Drug Prices?


AMA, doctor groups join MultiPlan class action lawsuit against Cigna


What Is Driving Health Care Spending Upward In States With Cost Growth Targets?


6 hospital, health system deals called off this year


The Clearest Road To An ACA Public Option Runs Through The States